You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 20, May 28, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (57)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in JAMA
 Topic Collections
 •Prostate Disease
 •Diagnosis
 •Oncology
 •Prostate Cancer
 •Pathology & Laboratory Medicine
 •Alert me on articles by topic

Variation of Serum Prostate-Specific Antigen Levels

An Evaluation of Year-to-Year Fluctuations

James A. Eastham, MD; Elyn Riedel, MA; Peter T. Scardino, MD; Moshe Shike, MD; Martin Fleisher, PhD; Arthur Schatzkin, MD, DrPh; Elaine Lanza, PhD; Lianne Latkany, MS; Colin B. Begg, PhD; for the Polyp Prevention Trial Study Group

JAMA. 2003;289:2695-2700.

Context  Serum prostate-specific antigen (PSA) testing is frequently used in early detection programs for prostate cancer. While PSA testing has resulted in an increase in prostate cancer detection, its routine use has been questioned because of a lack of specificity.

Objective  To determine whether year-to-year fluctuations in PSA levels are due to natural variation and render a single PSA test result unreliable.

Design, Setting, and Participants  Retrospective analysis of an unscreened population of 972 men (median age, 62 years) participating in the Polyp Prevention Trial (1991-1998). Five consecutive blood samples were obtained during a 4-year period and were assessed for total and free PSA levels.

Main Outcome Measure  Abnormal PSA test result based on a PSA level higher than 4 ng/mL; a PSA level higher than 2.5 ng/mL; a PSA level above the age-specific cutoff; a PSA level in the range of 4 to 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL; or a PSA velocity higher than 0.75 ng/mL per year.

Results  Prostate biopsy would have been recommended in 207 participants (21%) with a PSA level higher than 4 ng/mL; in 358 (37%) with a level higher than 2.5 ng/mL; in 172 (18%) with a level above the age-specific cutoff; in 190 (20%) with a level between 4 and 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL; and in 145 (15%) with a velocity higher than 0.75 ng/mL per year. Among men with an abnormal PSA finding, a high proportion had a normal PSA finding at 1 or more subsequent visits during 4-year follow-up: 68 (44%) of 154 participants with a PSA level higher than 4 ng/mL; 116 (40%) of 291 had a level higher than 2.5 ng/mL; 64 (55%) of 117 had an elevated level above the age-specific cutoff; and 76 (53%) of 143 had a level between 4 and 10 ng/mL and a free-to-total ratio of less than 0.25 ng/mL.

Conclusion  An isolated elevation in PSA level should be confirmed several weeks later before proceeding with further testing, including prostate biopsy.


Author Affiliations: Memorial Sloan-Kettering Cancer Center, New York, NY (Drs Eastham, Scardino, Shike, Fleisher, and Begg, and Mss Riedel and Latkany); and Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md (Drs Schatzkin and Lanza).


RELATED LETTER

Reliability and Validity of Prostate-Specific Antigen
Matti Hakama and Anssi Auvinen
JAMA. 2003;290(13):1705.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Detecting Trends in Noisy Data Series: Application to Biomarker Series
Bellera et al.
Am J Epidemiol 2008;167:1130-1139.
ABSTRACT | FULL TEXT  

Deciphering Protein Molecular Signatures in Cancer Tissues to Aid in Diagnosis, Prognosis, and Therapy
Caprioli
Cancer Res. 2005;65:10642-10645.
ABSTRACT | FULL TEXT  

Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002
Saraiya et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:2178-2182.
ABSTRACT | FULL TEXT  

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice
Soletormos et al.
Clin. Chem. 2005;51:1342-1351.
ABSTRACT | FULL TEXT  

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial
Andriole et al.
JNCI J Natl Cancer Inst 2005;97:433-438.
ABSTRACT | FULL TEXT  

PSA Velocity and Prostate Cancer
Dodd et al.
NEJM 2004;351:1800-1802.
FULL TEXT  

High result in prostate specific antigen test: Repeated testing and free tests might help
Davis
BMJ 2003;327:1227-1227.
FULL TEXT  

Reliability and Validity of Prostate-Specific Antigen
Hakama and Auvinen
JAMA 2003;290:1705-1705.
FULL TEXT  

How Stable Are Serum PSA Levels?
JWatch General 2003;2003:1-1.
FULL TEXT  

Prostate specific antigen test must be repeated before biopsy
Gottlieb
BMJ 2003;326:1231-1231.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.